Paola De Giorgio

发表

Determination of 1-aryl-4-propylpiperazine pKa values: the substituent on aryl modulates basicity.

E. Lacivita, M. Leopoldo, F. Berardi, 2009, Bioorganic & medicinal chemistry.

Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D3 receptors.

Francesco Berardi, Roberto Perrone, E. Lacivita, 2006, Journal of medicinal chemistry.

Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands.

Vincenzo Tortorella, Francesco Berardi, Roberto Perrone, 2002, Journal of medicinal chemistry.

3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.

E. Lacivita, M. Leopoldo, A. Khlebnikov, 2013, Biochemical pharmacology.

Synthesis, radiolabeling and in vivo evaluation of [(11)C](R)-1-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]-3-(2-pyrazinyloxy)-2-propanol, a potential PET radioligand for the 5-HT(7) receptor.

G. Knudsen, E. Lacivita, M. Leopoldo, 2014, European journal of medicinal chemistry.

Towards metabolically stable 5-HT7 receptor ligands: a study on 1-arylpiperazine derivatives and related isosters

E. Lacivita, M. Leopoldo, F. Berardi, 2013, Experimental Brain Research.

Investigations on the 1-(2-biphenyl)piperazine motif: identification of new potent and selective ligands for the serotonin(7) (5-HT(7)) receptor with agonist or antagonist action in vitro or ex vivo.

P. Svenningsson, E. Lacivita, M. Leopoldo, 2012, Journal of medicinal chemistry.

Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III.

E. Lacivita, M. Leopoldo, F. Berardi, 2008, Journal of medicinal chemistry.

Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands with optimal lipophilicity for brain imaging of the dopamine D3 receptor. Part II.

E. Lacivita, M. Leopoldo, F. Berardi, 2009, Bioorganic & medicinal chemistry.

The therapeutic potential of 5-HT1A receptors: a patent review

E. Lacivita, M. Leopoldo, F. Berardi, 2012, Expert opinion on therapeutic patents.

Structure-activity relationship study towards non-peptidic positron emission tomography (PET) radiotracer for gastrin releasing peptide receptors: Development of [18F] (S)-3-(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy)pyridin-2-yl]cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl)ureido]propionamide.

E. Lacivita, M. Leopoldo, R. Perrone, 2017, Bioorganic & medicinal chemistry.

Design, synthesis, radiolabeling, and in vivo evaluation of carbon-11 labeled N-[2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a potential positron emission tomography tracer for the dopamine D(4) receptors.

T. Suhara, E. Lacivita, M. Leopoldo, 2010, Journal of medicinal chemistry.

Determination of 1-aryl-4-propylpiperazine pKa values: the substituent on aryl modulates basicity.

E. Lacivita, M. Leopoldo, F. Berardi, 2009, Bioorganic & medicinal chemistry.

Synthesis, radiolabeling and in vivo evaluation of [(11)C](R)-1-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]-3-(2-pyrazinyloxy)-2-propanol, a potential PET radioligand for the 5-HT(7) receptor.

G. Knudsen, E. Lacivita, M. Leopoldo, 2014, European journal of medicinal chemistry.